{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:52:01Z","timestamp":1788792721141,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The preferable antigen delivery profile accompanied by sufficient adjuvants favors vaccine efficiency. Mitochondria, which feature prokaryotic characteristics and contain various damage-associated molecular patterns (DAMPs), are easily taken up by phagocytes and simultaneously activate innate immunity. In the current study, we established a mitochondria engineering platform for generating antigen-enriched mitochondria as cancer vaccine. Ovalbumin (OVA) and tyrosinase-related protein 2 (TRP2) were used as model antigens to synthesize fusion proteins with mitochondria-localized signal peptides. The lentiviral infection system was then employed to produce mitochondrial vaccines containing either OVA or TRP2. Engineered OVA- and TRP2-containing mitochondria (OVA-MITO and TRP2-MITO) were extracted and evaluated as potential cancer vaccines. Impressively, the engineered mitochondria vaccine demonstrated efficient antitumor effects when used as both prophylactic and therapeutic vaccines in murine tumor models. Mechanistically, OVA-MITO and TRP2-MITO potently recruited and activated dendritic cells (DCs) and induced a tumor-specific cell-mediated immunity. Moreover, DC activation by mitochondria vaccine critically involves TLR2 pathway and its lipid agonist, namely, cardiolipin derived from the mitochondrial membrane. The results demonstrated that engineered mitochondria are natively well-orchestrated carriers full of immune stimulants for antigen delivery, which could preferably target local dendritic cells and exert strong adaptive cellular immunity. This proof-of-concept study established a universal platform for vaccine construction with engineered mitochondria bearing alterable antigens for cancers as well as other diseases.<\/jats:p>","DOI":"10.1038\/s41423-024-01203-4","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T09:02:28Z","timestamp":1724144548000},"page":"1251-1265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Engineered mitochondria exert potent antitumor immunity as a cancer vaccine platform"],"prefix":"10.1038","volume":"21","author":[{"given":"Jingwen","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-2301","authenticated-orcid":false,"given":"Weiqi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxia","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunju","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfei","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-1895","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-0495","authenticated-orcid":false,"given":"Chong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-6422","authenticated-orcid":false,"given":"Xiawei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"1203_CR1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360\u201378.","journal-title":"Nat Rev Cancer"},{"key":"1203_CR2","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1158\/1078-0432.CCR-18-1728","volume":"25","author":"P Probst","year":"2019","unstructured":"Probst P, Stringhini M, Ritz D, Fugmann T, Neri D. Antibody-based delivery of TNF to the tumor neovasculature potentiates the therapeutic activity of a peptide anticancer vaccine. Clin Cancer Res. 2019;25:698\u2013709.","journal-title":"Clin Cancer Res"},{"key":"1203_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13368-y","volume":"10","author":"CR Perez","year":"2019","unstructured":"Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 2019;10:5408.","journal-title":"Nat Commun"},{"key":"1203_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","volume":"38","author":"A Lopes","year":"2019","unstructured":"Lopes A, Vandermeulen G, Pr\u00e9at V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res. 2019;38:146.","journal-title":"J Exp Clin Cancer Res"},{"key":"1203_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","volume":"10","author":"N Tatsis","year":"2004","unstructured":"Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther. 2004;10:616\u201329.","journal-title":"Mol Ther"},{"key":"1203_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00281-018-0691-z","volume":"41","author":"T Tran","year":"2019","unstructured":"Tran T, Blanc C, Granier C, Saldmann A, Tanchot C, Tartour E. Therapeutic cancer vaccine: building the future from lessons of the past. Semin Immunopathol. 2019;41:69\u201385.","journal-title":"Semin Immunopathol"},{"key":"1203_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/eji.200737995","volume":"38","author":"MS Bijker","year":"2008","unstructured":"Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R. Superior induction of Antitumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol. 2008;38:1033\u201342.","journal-title":"Eur J Immunol"},{"key":"1203_CR8","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1016\/j.vaccine.2011.04.082","volume":"29","author":"X Huang","year":"2011","unstructured":"Huang X, Ye D, Thorpe PE. Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. Vaccine. 2011;29:4785\u201393.","journal-title":"Vaccine"},{"key":"1203_CR9","doi-asserted-by":"publisher","first-page":"8085","DOI":"10.1158\/0008-5472.CAN-04-1871","volume":"64","author":"MW Graner","year":"2004","unstructured":"Graner MW, Likhacheva A, Davis J, Raymond A, Brandenberger J, Romanoski A, et al. Cargo from tumor-expressed albumin inhibits T-cell activation and responses. Cancer Res. 2004;64:8085\u201392.","journal-title":"Cancer Res"},{"key":"1203_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1053\/j.seminoncol.2012.02.010","volume":"39","author":"RA Madan","year":"2012","unstructured":"Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol. 2012;39:296\u2013304.","journal-title":"Semin Oncol"},{"key":"1203_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37:1051\u201361.","journal-title":"J Clin Oncol"},{"key":"1203_CR12","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.ymthe.2021.03.002","volume":"29","author":"SW Tse","year":"2021","unstructured":"Tse SW, McKinney K, Walker W, Nguyen M, Iacovelli J, Small C, et al. mRNA-encoded, constitutively active STING(V155M) is a potent genetic adjuvant of antigen-specific CD8(+) T cell response. Mol Ther. 2021;29:2227\u201338.","journal-title":"Mol Ther"},{"key":"1203_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/imr.12586","volume":"280","author":"Y Ma","year":"2017","unstructured":"Ma Y, Pitt JM, Li Q, Yang H. The renaissance of anti-neoplastic immunity from tumor cell demise. Immunol Rev. 2017;280:194\u2013206.","journal-title":"Immunol Rev"},{"key":"1203_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41587-019-0390-x","volume":"38","author":"GM Lynn","year":"2020","unstructured":"Lynn GM, Sedlik C, Baharom F, Zhu Y, Ramirez-Valdez RA, Coble VL, et al. Peptide-TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat Biotechnol. 2020;38:320\u201332.","journal-title":"Nat Biotechnol"},{"key":"1203_CR15","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.addr.2013.05.013","volume":"65","author":"AM Hafner","year":"2013","unstructured":"Hafner AM, Corth\u00e9sy B, Merkle HP. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev. 2013;65:1386\u201399.","journal-title":"Adv Drug Deliv Rev"},{"key":"1203_CR16","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1038\/s41423-020-0456-1","volume":"18","author":"C Fang","year":"2021","unstructured":"Fang C, Mo F, Liu L, Du J, Luo M, Men K, et al. Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccine. Cell Mol Immunol. 2021;18:2211\u201323.","journal-title":"Cell Mol Immunol"},{"key":"1203_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202102781","volume":"11","author":"Z Zheng","year":"2022","unstructured":"Zheng Z, Lin M, Lu W, Huang P, Zheng Y, Zhang X, et al. In situ tumor vaccination with calcium-linked degradable coacervate nanocomplex co-delivering photosensitizer and TLR7\/8 agonist to trigger effective Antitumor immune responses. Adv Health Mater. 2022;11:e2102781.","journal-title":"Adv Health Mater"},{"key":"1203_CR18","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1158\/0008-5472.CAN-06-0206","volume":"66","author":"MH den Brok","year":"2006","unstructured":"den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Toonen LW, Figdor CG, et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res. 2006;66:7285\u201392.","journal-title":"Cancer Res"},{"key":"1203_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nri2975","volume":"11","author":"AP West","year":"2011","unstructured":"West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. Nat Rev Immunol. 2011;11:389\u2013402.","journal-title":"Nat Rev Immunol"},{"key":"1203_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s13238-015-0222-9","volume":"7","author":"C Fang","year":"2016","unstructured":"Fang C, Wei X, Wei Y, Mitochondrial DNA. in the regulation of innate immune responses. Protein Cell. 2016;7:11\u201316.","journal-title":"Protein Cell"},{"key":"1203_CR21","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.4049\/jimmunol.1500281","volume":"195","author":"S Pierini","year":"2015","unstructured":"Pierini S, Fang C, Rafail S, Facciponte JG, Huang J, De Sanctis F, et al. A tumor mitochondria vaccine protects against experimental renal cell carcinoma. J Immunol. 2015;195:4020\u20137.","journal-title":"J Immunol"},{"key":"1203_CR22","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.7150\/thno.21693","volume":"8","author":"L Liu","year":"2018","unstructured":"Liu L, Liu Y, Xu B, Liu C, Jia Y, Liu T, et al. Negative regulation of cationic nanoparticle-induced inflammatory toxicity through the increased production of prostaglandin E2 via mitochondrial DNA-activated Ly6C(+) monocytes. Theranostics. 2018;8:3138\u201352.","journal-title":"Theranostics"},{"key":"1203_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1083\/jcb.105.2.669","volume":"105","author":"AL Horwich","year":"1987","unstructured":"Horwich AL, Kalousek F, Fenton WA, Furtak K, Pollock RA, Rosenberg LE. The ornithine transcarbamylase leader peptide directs mitochondrial import through both its midportion structure and net positive charge. J Cell Biol. 1987;105:669\u201377.","journal-title":"J Cell Biol"},{"key":"1203_CR24","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1021\/acs.nanolett.8b05188","volume":"19","author":"W Chen","year":"2019","unstructured":"Chen W, Shi K, Chu B, Wei X, Qian Z. Mitochondrial surface engineering for multidrug resistance reversal. Nano Lett. 2019;19:2905\u201313.","journal-title":"Nano Lett"},{"key":"1203_CR25","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. 2022;40:1010\u20131026.e11.","journal-title":"Cancer Cell"},{"key":"1203_CR26","doi-asserted-by":"publisher","first-page":"e003480","DOI":"10.1136\/jitc-2021-003480","volume":"9","author":"AM D'Alise","year":"2021","unstructured":"D'Alise AM, Leoni G, De Lucia M, Langone F, Nocchi L, Tucci FG, et al. Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion. J Immunother Cancer. 2021;9:e003480.","journal-title":"J Immunother Cancer"},{"key":"1203_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","volume":"38","author":"AD Garg","year":"2017","unstructured":"Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol. 2017;38:577\u201393.","journal-title":"Trends Immunol"},{"key":"1203_CR28","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.4049\/jimmunol.174.7.4070","volume":"174","author":"L Riol-Blanco","year":"2005","unstructured":"Riol-Blanco L, S\u00e1nchez-S\u00e1nchez N, Torres A, Tejedor A, Narumiya S, Corb\u00ed AL, et al. The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J Immunol. 2005;174:4070\u201380.","journal-title":"J Immunol"},{"key":"1203_CR29","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","volume":"37","author":"A Gardner","year":"2016","unstructured":"Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37:855\u201365.","journal-title":"Trends Immunol"},{"key":"1203_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cellimm.2008.08.007","volume":"254","author":"E Aktas","year":"2009","unstructured":"Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 2009;254:149\u201354.","journal-title":"Cell Immunol"},{"key":"1203_CR31","doi-asserted-by":"publisher","first-page":"11986","DOI":"10.1002\/jcp.27856","volume":"234","author":"D Rostamzadeh","year":"2019","unstructured":"Rostamzadeh D, Haghshenas MR, Daryanoosh F, Samadi M, Hosseini A, Ghaderi A, et al. Altered frequency of CD8(+) CD11c(+) T cells and expression of immunosuppressive molecules in lymphoid organs of mouse model of colorectal cancer. J Cell Physiol. 2019;234:11986\u201398.","journal-title":"J Cell Physiol"},{"key":"1203_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","volume":"27","author":"X Cao","year":"2007","unstructured":"Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27:635\u201346.","journal-title":"Immunity"},{"key":"1203_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/cr.2017.14","volume":"27","author":"M Luo","year":"2017","unstructured":"Luo M, Shao B, Yu JY, Liu T, Liang X, Lu L, et al. Simultaneous enhancement of cellular and humoral immunity by the high salt formulation of Al(OH)(3) adjuvant. Cell Res. 2017;27:586\u20139.","journal-title":"Cell Res"},{"key":"1203_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1084\/jem.190.5.617","volume":"190","author":"T Nishimura","year":"1999","unstructured":"Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med. 1999;190:617\u201327.","journal-title":"J Exp Med"},{"key":"1203_CR35","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/cr.2017.14","volume":"27","author":"M Luo","year":"2017","unstructured":"Luo M, Shao B, Yu JY, Liu T, Liang X, Lu L, et al. Simultaneous enhancement of cellular and humoral immunity by the high salt formulation of Al(OH)3 adjuvant. Cell Res. 2017;27:586\u20139.","journal-title":"Cell Res"},{"key":"1203_CR36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/eji.201747222","volume":"48","author":"JA Cho","year":"2018","unstructured":"Cho JA, Kim TJ, Moon HJ, Kim YJ, Yoon HK, Seong SY. Cardiolipin activates antigen-presenting cells via TLR2-PI3K-PKN1-AKT\/p38-NF-kB signaling to prime antigen-specific na\u00efve T cells in mice. Eur J Immunol. 2018;48:777\u201390.","journal-title":"Eur J Immunol"},{"key":"1203_CR37","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1126\/science.abq1053","volume":"381","author":"KC Mangalhara","year":"2023","unstructured":"Mangalhara KC, Varanasi SK, Johnson MA, Burns MJ, Rojas GR, Esparza Molt\u00f3 PB, et al. Manipulating mitochondrial electron flow enhances tumor immunogenicity. Science. 2023;381:1316\u201323.","journal-title":"Science"},{"key":"1203_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300286","volume":"10","author":"S Wu","year":"2023","unstructured":"Wu S, Zhang H, Wang S, Sun J, Hu Y, Liu H, et al. In situ vaccination with mitochondria-targeting immunogenic death inducer elicits CD8(+) T cell-dependent antitumor immunity to boost tumor immunotherapy. Adv Sci. 2023;10:e2300286.","journal-title":"Adv Sci"},{"key":"1203_CR39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41586-023-05770-w","volume":"615","author":"V Zecchini","year":"2023","unstructured":"Zecchini V, Paupe V, Herranz-Montoya I, Janssen J, Wortel I, Morris JL, et al. Fumarate induces vesicular release of mtDNA to drive innate immunity. Nature. 2023;615:499\u2013506.","journal-title":"Nature"},{"key":"1203_CR40","doi-asserted-by":"publisher","first-page":"e113258","DOI":"10.15252\/embj.2022113258","volume":"42","author":"T Zhao","year":"2023","unstructured":"Zhao T, Zhang J, Lei H, Meng Y, Cheng H, Zhao Y, et al. NRF1-mediated mitochondrial biogenesis antagonizes innate antiviral immunity. EMBO J. 2023;42:e113258.","journal-title":"EMBO J"},{"key":"1203_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1146\/annurev-biochem-032620-104401","volume":"92","author":"LE Newman","year":"2023","unstructured":"Newman LE, Shadel GS. Mitochondrial DNA release in innate immune signaling. Annu Rev Biochem 2023;92:299\u2013332.","journal-title":"Annu Rev Biochem"},{"key":"1203_CR42","first-page":"52","volume":"202","author":"B Banoth","year":"2018","unstructured":"Banoth B, Cassel SL. Mitochondria in innate immune signaling. Transl Res J Lab Clin Med. 2018;202:52\u201368.","journal-title":"Transl Res J Lab Clin Med"},{"key":"1203_CR43","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/ni.3704","volume":"18","author":"EL Mills","year":"2017","unstructured":"Mills EL, Kelly B, O\u2019Neill LAJ. Mitochondria are the powerhouses of immunity. Nat Immunol. 2017;18:488\u201398.","journal-title":"Nat Immunol"},{"key":"1203_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34897-z","volume":"13","author":"MP Cervantes-Silva","year":"2022","unstructured":"Cervantes-Silva MP, Carroll RG, Wilk MM, Moreira D, Payet CA, O'Siorain JR, et al. The circadian clock influences T cell responses to vaccination by regulating dendritic cell antigen processing. Nat Commun. 2022;13:7217.","journal-title":"Nat Commun"},{"key":"1203_CR45","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/387493a0","volume":"387","author":"BF Lang","year":"1997","unstructured":"Lang BF, Burger G, O'Kelly CJ, Cedergren R, Golding GB, Lemieux C, et al. An ancestral mitochondrial DNA resembling a eubacterial genome in miniature. Nature. 1997;387:493\u20137.","journal-title":"Nature"},{"key":"1203_CR46","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature08780","volume":"464","author":"Q Zhang","year":"2010","unstructured":"Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104\u20137.","journal-title":"Nature"},{"key":"1203_CR47","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jconrel.2020.09.007","volume":"327","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Sato Y, Nakamura T, Harashima H. Evolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine. J Control Release. 2020;327:533\u201345.","journal-title":"J Control Release"},{"key":"1203_CR48","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309\u201337.","journal-title":"Cell"},{"key":"1203_CR49","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","volume":"22","author":"KF Bol","year":"2016","unstructured":"Bol KF, Schreibelt G, Gerritsen WR, de Vries IJM, Figdor CG. Dendritic cell\u2013based immunotherapy: state of the art and beyond. Clin Cancer Res. 2016;22:1897\u2013906.","journal-title":"Clin Cancer Res"},{"key":"1203_CR50","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00262-016-1796-7","volume":"65","author":"KF Bol","year":"2016","unstructured":"Bol KF, Aarntzen EH, Pots JM, Olde Nordkamp MA, van de Rakt MW, Scharenborg NM, et al. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective Antitumor responses in melanoma patients at the cost of toxicity. Cancer Immunol Immunother. 2016;65:327\u201339.","journal-title":"Cancer Immunol Immunother"},{"key":"1203_CR51","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.smim.2010.03.002","volume":"22","author":"P Kalinski","year":"2010","unstructured":"Kalinski P, Okada H. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol. 2010;22:173\u201382.","journal-title":"Semin Immunol"},{"key":"1203_CR52","doi-asserted-by":"publisher","first-page":"232ra251","DOI":"10.1126\/scitranslmed.3008068","volume":"6","author":"MV Dhodapkar","year":"2014","unstructured":"Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, et al. Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205. Sci Transl Med. 2014;6:232ra251\u2013232ra251.","journal-title":"Sci Transl Med"},{"key":"1203_CR53","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/cas.12824","volume":"106","author":"T Seya","year":"2015","unstructured":"Seya T, Shime H, Takeda Y, Tatematsu M, Takashima K, Matsumoto M. Adjuvant for vaccine immunotherapy of cancer \u2013 focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci. 2015;106:1659\u201368.","journal-title":"Cancer Sci"},{"key":"1203_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105017","volume":"159","author":"L Bai","year":"2020","unstructured":"Bai L, Li W, Zheng W, Xu D, Chen N, Cui J. Promising targets based on pattern recognition receptors for cancer immunotherapy. Pharm Res. 2020;159:105017.","journal-title":"Pharm Res"},{"key":"1203_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw6071","volume":"6","author":"Q Ni","year":"2020","unstructured":"Ni Q, Zhang F, Liu Y, Wang Z, Yu G, Liang B, et al. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci Adv. 2020;6:eaaw6071.","journal-title":"Sci Adv"},{"key":"1203_CR56","doi-asserted-by":"publisher","first-page":"E4478","DOI":"10.1073\/pnas.1410293111","volume":"111","author":"M Oosting","year":"2014","unstructured":"Oosting M, Cheng SC, Bolscher JM, Vestering-Stenger R, Plantinga TS, Verschueren IC, et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc Natl Acad Sci USA. 2014;111:E4478\u20134484.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1203_CR57","doi-asserted-by":"publisher","first-page":"e18833","DOI":"10.1371\/journal.pone.0018833","volume":"6","author":"S Yamazaki","year":"2011","unstructured":"Yamazaki S, Okada K, Maruyama A, Matsumoto M, Yagita H, Seya T. TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective Antitumor immunity induced by Pam2 lipopeptides in vivo. PloS one. 2011;6:e18833.","journal-title":"PloS one"},{"key":"1203_CR58","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/cas.13576","volume":"109","author":"T Akazawa","year":"2018","unstructured":"Akazawa T, Ohashi T, Wijewardana V, Sugiura K, Inoue N. Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands. Cancer Sci. 2018;109:1319\u201329.","journal-title":"Cancer Sci"},{"key":"1203_CR59","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/eji.201747222","volume":"48","author":"JA Cho","year":"2018","unstructured":"Cho JA, Kim TJ, Moon HJ, Kim YJ, Yoon HK, Seong SY. Cardiolipin activates antigen\u2010presenting cells via TLR2\u2010PI3K\u2010PKN1\u2010AKT\/p38\u2010NF\u2010kB signaling to prime antigen\u2010specific na\u00efve T cells in mice. Eur J Immunol. 2018;48:777\u201390.","journal-title":"Eur J Immunol"},{"key":"1203_CR60","doi-asserted-by":"publisher","first-page":"14144","DOI":"10.1073\/pnas.241340898","volume":"98","author":"C Laloi","year":"2001","unstructured":"Laloi C, Rayapuram N, Chartier Y, Grienenberger JM, Bonnard G, Meyer Y. Identification and characterization of a mitochondrial thioredoxin system in plants. Proc Natl Acad Sci. 2001;98:14144\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"1203_CR61","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1002\/eji.1830271209","volume":"27","author":"H Jonuleit","year":"1997","unstructured":"Jonuleit H, K\u00fchn U, M\u00fcller G, Steinbrink K, Paragnik L, Schmitt E, et al. Pro\u2010inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum\u2010free conditions. Eur J Immunol. 1997;27:3135\u201342.","journal-title":"Eur J Immunol"},{"key":"1203_CR62","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.7150\/thno.4525","volume":"2","author":"Y Guo","year":"2012","unstructured":"Guo Y, Liu X, Sun X, Zhang Q, Gong T, Zhang Z. Mannosylated lipid nano-emulsions loaded with lycorine-oleic acid ionic complex for tumor cell-specific delivery. Theranostics. 2012;2:1104\u201314.","journal-title":"Theranostics"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-024-01203-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-024-01203-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-024-01203-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T11:03:48Z","timestamp":1730372628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-024-01203-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":62,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["1203"],"URL":"https:\/\/doi.org\/10.1038\/s41423-024-01203-4","relation":{},"ISSN":["2042-0226"],"issn-type":[{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}